PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28842166-6 2017 For identifying the role of anti-cancer drug response, knockdown of p21 overcomes cisplatin and poly-(ADP-ribose) polymerase (PARP) inhibitor-mediated growth suppression in CHD4-depleted cells. Cisplatin 82-91 cyclin dependent kinase inhibitor 1A Homo sapiens 68-71 29871302-8 2017 The combination of metformin and 5-fluorouracil produced an antagonism action in Hep-2 cells.Western blot assay showed that metformin, cisplatin, 5-fluorouracil could have caused the increase of expression level of AMPK-alpha, P21 and Cyclin D1 in Hep-2 cells while Paclitaxel could have cause the decrease of expression level of Cyclin D1. Cisplatin 135-144 cyclin dependent kinase inhibitor 1A Homo sapiens 227-230 27559850-0 2016 DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21WAF1/CIP1. Cisplatin 73-82 cyclin dependent kinase inhibitor 1A Homo sapiens 115-119 28081228-9 2017 However, upon hypoxia the cisplatin-induced cell cycle arrest and expression of p53 and p21 were abrogated. Cisplatin 26-35 cyclin dependent kinase inhibitor 1A Homo sapiens 88-91 27559850-8 2016 Furthermore, we identified CDKN1A (p21) as a functional target of miR-33b-3p, a critical regulator of G1/S checkpoint, which potentially mediated the protection effects of miR-33b-3p against cisplatin. Cisplatin 191-200 cyclin dependent kinase inhibitor 1A Homo sapiens 27-33 27559850-8 2016 Furthermore, we identified CDKN1A (p21) as a functional target of miR-33b-3p, a critical regulator of G1/S checkpoint, which potentially mediated the protection effects of miR-33b-3p against cisplatin. Cisplatin 191-200 cyclin dependent kinase inhibitor 1A Homo sapiens 35-38 26392091-4 2016 The analysis of the changes in the expression of genes involved in the response to DNA damage (CDKN1A, GADD45A, MDM2), apoptosis (BAX, BCL2) and oncogenesis (MYC, JUN) showed that 5-FU, CDDP and ET upregulated the genes involved in DNA damage response, while the anti-apoptotic gene BCL2 and oncogene MYC were downregulated. Cisplatin 186-190 cyclin dependent kinase inhibitor 1A Homo sapiens 95-101 24921914-0 2014 MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G1/S transition and apoptosis by targeting p21(WAF1/CIP1). Cisplatin 75-84 cyclin dependent kinase inhibitor 1A Homo sapiens 143-146 26984736-0 2016 Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation. Cisplatin 85-94 cyclin dependent kinase inhibitor 1A Homo sapiens 136-140 26984736-2 2016 In Cisplatin-sensitive cells Cisplatin treatment increases p53-protein level as well as downstream signaling, e.g., expression of p21(Waf1/Cip1), Bax, Noxa, MDM2, and activation of Caspase-9/-3. Cisplatin 3-12 cyclin dependent kinase inhibitor 1A Homo sapiens 130-133 26984736-2 2016 In Cisplatin-sensitive cells Cisplatin treatment increases p53-protein level as well as downstream signaling, e.g., expression of p21(Waf1/Cip1), Bax, Noxa, MDM2, and activation of Caspase-9/-3. Cisplatin 3-12 cyclin dependent kinase inhibitor 1A Homo sapiens 134-138 26984736-2 2016 In Cisplatin-sensitive cells Cisplatin treatment increases p53-protein level as well as downstream signaling, e.g., expression of p21(Waf1/Cip1), Bax, Noxa, MDM2, and activation of Caspase-9/-3. Cisplatin 3-12 cyclin dependent kinase inhibitor 1A Homo sapiens 139-143 26984736-2 2016 In Cisplatin-sensitive cells Cisplatin treatment increases p53-protein level as well as downstream signaling, e.g., expression of p21(Waf1/Cip1), Bax, Noxa, MDM2, and activation of Caspase-9/-3. Cisplatin 29-38 cyclin dependent kinase inhibitor 1A Homo sapiens 130-133 26984736-2 2016 In Cisplatin-sensitive cells Cisplatin treatment increases p53-protein level as well as downstream signaling, e.g., expression of p21(Waf1/Cip1), Bax, Noxa, MDM2, and activation of Caspase-9/-3. Cisplatin 29-38 cyclin dependent kinase inhibitor 1A Homo sapiens 134-138 26482648-6 2015 RESULTS: The low expressions of miR-17 and miR-92 families can maintain cisplatin resistance through the regulation of CDKN1A and RAD21. Cisplatin 72-81 cyclin dependent kinase inhibitor 1A Homo sapiens 119-125 26482648-7 2015 As a result of high expressions of CDKN1A and RAD21, the inhibition of DNA synthesis and the repair of DNA damage are achieved and these may be two major contributing factors to cisplatin resistance. Cisplatin 178-187 cyclin dependent kinase inhibitor 1A Homo sapiens 35-41 26984736-2 2016 In Cisplatin-sensitive cells Cisplatin treatment increases p53-protein level as well as downstream signaling, e.g., expression of p21(Waf1/Cip1), Bax, Noxa, MDM2, and activation of Caspase-9/-3. Cisplatin 29-38 cyclin dependent kinase inhibitor 1A Homo sapiens 139-143 26984736-7 2016 Our data indicate 1) that expression/activity of LRRC8A is essential for Cisplatin-induced increase in p53 protein level and its downstream signaling, i.e., Caspase-9/-3 activation, expression of p21(Waf1/Cip1) and MDM2; and 2) that downregulation of LRRC8A-dependent osmolyte transporters contributes to acquirement of Cisplatin resistance in ovarian and lung carcinoma cells. Cisplatin 73-82 cyclin dependent kinase inhibitor 1A Homo sapiens 196-199 26984736-7 2016 Our data indicate 1) that expression/activity of LRRC8A is essential for Cisplatin-induced increase in p53 protein level and its downstream signaling, i.e., Caspase-9/-3 activation, expression of p21(Waf1/Cip1) and MDM2; and 2) that downregulation of LRRC8A-dependent osmolyte transporters contributes to acquirement of Cisplatin resistance in ovarian and lung carcinoma cells. Cisplatin 73-82 cyclin dependent kinase inhibitor 1A Homo sapiens 200-204 26984736-7 2016 Our data indicate 1) that expression/activity of LRRC8A is essential for Cisplatin-induced increase in p53 protein level and its downstream signaling, i.e., Caspase-9/-3 activation, expression of p21(Waf1/Cip1) and MDM2; and 2) that downregulation of LRRC8A-dependent osmolyte transporters contributes to acquirement of Cisplatin resistance in ovarian and lung carcinoma cells. Cisplatin 73-82 cyclin dependent kinase inhibitor 1A Homo sapiens 205-209 24155936-0 2013 The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression. Cisplatin 45-54 cyclin dependent kinase inhibitor 1A Homo sapiens 123-136 24155936-8 2013 Also, pcDNA/p21or siRNA/p21 could mimic the effects of siRNA/HOTAIR1 or pcDNA/HOTAIR on the sensitivity of LAD cells to cisplatin. Cisplatin 120-129 cyclin dependent kinase inhibitor 1A Homo sapiens 12-15 24155936-8 2013 Also, pcDNA/p21or siRNA/p21 could mimic the effects of siRNA/HOTAIR1 or pcDNA/HOTAIR on the sensitivity of LAD cells to cisplatin. Cisplatin 120-129 cyclin dependent kinase inhibitor 1A Homo sapiens 24-27 24155936-9 2013 Importantly, siRNA/p21 or pcDNA/p21 could partially rescue the effects of siRNA/HOTAIR1 or pcDNA/HOTAIR on both p21 expression and cisplatin sensitivity in LAD cells. Cisplatin 131-140 cyclin dependent kinase inhibitor 1A Homo sapiens 19-22 24155936-9 2013 Importantly, siRNA/p21 or pcDNA/p21 could partially rescue the effects of siRNA/HOTAIR1 or pcDNA/HOTAIR on both p21 expression and cisplatin sensitivity in LAD cells. Cisplatin 131-140 cyclin dependent kinase inhibitor 1A Homo sapiens 32-35 24155936-9 2013 Importantly, siRNA/p21 or pcDNA/p21 could partially rescue the effects of siRNA/HOTAIR1 or pcDNA/HOTAIR on both p21 expression and cisplatin sensitivity in LAD cells. Cisplatin 131-140 cyclin dependent kinase inhibitor 1A Homo sapiens 32-35 24155936-10 2013 Further, HOTAIR was observed to be significantly downregulated in cisplatin-responding LAD tissues, and its expression was inversely correlated with p21 mRNA expression. Cisplatin 66-75 cyclin dependent kinase inhibitor 1A Homo sapiens 149-152 24155936-11 2013 Taken together, our findings suggest that upregulation of HOTAIR contributes to the cisplatin resistance of LAD cells, at least in part, through the regulation of p21 expression. Cisplatin 84-93 cyclin dependent kinase inhibitor 1A Homo sapiens 163-166 22673193-7 2012 Interestingly, cells treated with Twist1 siRNA displayed upregulation of p21(Waf1/CIP1), and suppression of p21(Waf1/CIP1) with specific siRNA further enhanced the cell death response to cisplatin/Twist1 siRNA. Cisplatin 187-196 cyclin dependent kinase inhibitor 1A Homo sapiens 108-111 23165211-6 2012 Following cisplatin exposure, expression levels of p53 increased, with a subsequent increase in MDM2 and p21 mRNA and protein levels and Fas cell membrane levels. Cisplatin 10-19 cyclin dependent kinase inhibitor 1A Homo sapiens 105-108 23165211-8 2012 In contrast, p53 suppression augmented cisplatin-induced apoptosis in Scha and 2102EP and concomitantly strongly suppressed MDM2 and p21 mRNA and protein expression. Cisplatin 39-48 cyclin dependent kinase inhibitor 1A Homo sapiens 133-136 23397083-7 2013 Moreover, beta-elemene and cisplatin in combination clearly decreased the protein levels of cyclin B1 and CDC25C and increased the levels of p21(Cip1/Waf1), p27(Kip1), and GADD45 in these cells, compared with the effects of either agent alone at the same concentration. Cisplatin 27-36 cyclin dependent kinase inhibitor 1A Homo sapiens 141-144 23397083-7 2013 Moreover, beta-elemene and cisplatin in combination clearly decreased the protein levels of cyclin B1 and CDC25C and increased the levels of p21(Cip1/Waf1), p27(Kip1), and GADD45 in these cells, compared with the effects of either agent alone at the same concentration. Cisplatin 27-36 cyclin dependent kinase inhibitor 1A Homo sapiens 145-149 23397083-7 2013 Moreover, beta-elemene and cisplatin in combination clearly decreased the protein levels of cyclin B1 and CDC25C and increased the levels of p21(Cip1/Waf1), p27(Kip1), and GADD45 in these cells, compared with the effects of either agent alone at the same concentration. Cisplatin 27-36 cyclin dependent kinase inhibitor 1A Homo sapiens 150-154 23560058-8 2013 The results identify two targetable 4N arrests that can contribute to cisplatin resistance: First, a prolonged G2 arrest that can be targeted by UCN-01, and second, a tetraploid G1 arrest that can be targeted by siRNA against p21. Cisplatin 70-79 cyclin dependent kinase inhibitor 1A Homo sapiens 226-229 22673193-7 2012 Interestingly, cells treated with Twist1 siRNA displayed upregulation of p21(Waf1/CIP1), and suppression of p21(Waf1/CIP1) with specific siRNA further enhanced the cell death response to cisplatin/Twist1 siRNA. Cisplatin 187-196 cyclin dependent kinase inhibitor 1A Homo sapiens 112-116 22673193-7 2012 Interestingly, cells treated with Twist1 siRNA displayed upregulation of p21(Waf1/CIP1), and suppression of p21(Waf1/CIP1) with specific siRNA further enhanced the cell death response to cisplatin/Twist1 siRNA. Cisplatin 187-196 cyclin dependent kinase inhibitor 1A Homo sapiens 117-121 21592546-6 2011 Cisplatin also potently inhibited G1-phase Cdk4/cyclin D1 and Cdk2/cyclin E activities at ~18 h. In agreement, exposure of cisplatin-treated A2780, HCT-116(p53-/-) and HCT-116(p21-/-) tumor cells to nocodazole revealed limited G1-arrest that was dependent on p53 and p21. Cisplatin 0-9 cyclin dependent kinase inhibitor 1A Homo sapiens 176-179 21843532-5 2011 However, UV, BP, 4NQO and cisplatin down-regulated p21 below basal levels. Cisplatin 26-35 cyclin dependent kinase inhibitor 1A Homo sapiens 51-54 21592546-6 2011 Cisplatin also potently inhibited G1-phase Cdk4/cyclin D1 and Cdk2/cyclin E activities at ~18 h. In agreement, exposure of cisplatin-treated A2780, HCT-116(p53-/-) and HCT-116(p21-/-) tumor cells to nocodazole revealed limited G1-arrest that was dependent on p53 and p21. Cisplatin 0-9 cyclin dependent kinase inhibitor 1A Homo sapiens 267-270 21592546-6 2011 Cisplatin also potently inhibited G1-phase Cdk4/cyclin D1 and Cdk2/cyclin E activities at ~18 h. In agreement, exposure of cisplatin-treated A2780, HCT-116(p53-/-) and HCT-116(p21-/-) tumor cells to nocodazole revealed limited G1-arrest that was dependent on p53 and p21. Cisplatin 123-132 cyclin dependent kinase inhibitor 1A Homo sapiens 176-179 21592546-6 2011 Cisplatin also potently inhibited G1-phase Cdk4/cyclin D1 and Cdk2/cyclin E activities at ~18 h. In agreement, exposure of cisplatin-treated A2780, HCT-116(p53-/-) and HCT-116(p21-/-) tumor cells to nocodazole revealed limited G1-arrest that was dependent on p53 and p21. Cisplatin 123-132 cyclin dependent kinase inhibitor 1A Homo sapiens 267-270 21087528-0 2010 p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell. Cisplatin 108-117 cyclin dependent kinase inhibitor 1A Homo sapiens 8-12 21325496-0 2011 Cdk2-dependent phosphorylation of p21 regulates the role of Cdk2 in cisplatin cytotoxicity. Cisplatin 68-77 cyclin dependent kinase inhibitor 1A Homo sapiens 34-37 21325496-2 2011 We found that an 18-kDa protein identified by mass spectrometry as p21(WAF1/Cip1) was phosphorylated by Cdk2 starting 12 h after cisplatin exposure. Cisplatin 129-138 cyclin dependent kinase inhibitor 1A Homo sapiens 67-70 21325496-2 2011 We found that an 18-kDa protein identified by mass spectrometry as p21(WAF1/Cip1) was phosphorylated by Cdk2 starting 12 h after cisplatin exposure. Cisplatin 129-138 cyclin dependent kinase inhibitor 1A Homo sapiens 71-75 21325496-2 2011 We found that an 18-kDa protein identified by mass spectrometry as p21(WAF1/Cip1) was phosphorylated by Cdk2 starting 12 h after cisplatin exposure. Cisplatin 129-138 cyclin dependent kinase inhibitor 1A Homo sapiens 76-80 21325496-4 2011 The adenoviral transduction of p21 before cisplatin exposure protects from cytotoxicity by inhibiting Cdk2. Cisplatin 42-51 cyclin dependent kinase inhibitor 1A Homo sapiens 31-34 21325496-5 2011 Although cisplatin causes induction of endogenous p21, the protection is inefficient. Cisplatin 9-18 cyclin dependent kinase inhibitor 1A Homo sapiens 50-53 21325496-6 2011 We hypothesized that phosphorylation of p21 at serine 78 could affect its role as a Cdk inhibitor, and thereby lessen its ability to protect from cisplatin cytotoxicity. Cisplatin 146-155 cyclin dependent kinase inhibitor 1A Homo sapiens 40-43 21325496-8 2011 Mutant p21(S78D) was an inefficient inhibitor of Cdk2 and was inefficient at protecting TKPTS cells from cisplatin-induced cell death. Cisplatin 105-114 cyclin dependent kinase inhibitor 1A Homo sapiens 7-10 21325496-9 2011 We conclude that phosphorylation of p21 by Cdk2 limits the effectiveness of p21 to inhibit Cdk2, which is the mechanism for continued cisplatin cytotoxicity even after the induction of a protective protein. Cisplatin 134-143 cyclin dependent kinase inhibitor 1A Homo sapiens 36-39 21325496-9 2011 We conclude that phosphorylation of p21 by Cdk2 limits the effectiveness of p21 to inhibit Cdk2, which is the mechanism for continued cisplatin cytotoxicity even after the induction of a protective protein. Cisplatin 134-143 cyclin dependent kinase inhibitor 1A Homo sapiens 76-79 21087528-5 2010 RESULTS: Enhanced p21 expression was observed in A549 cells after transfection of dsRNA, which was correlated with a significant growth inhibition and enhancement of chemosensitivity to cisplatin in A549 cells in vitro. Cisplatin 186-195 cyclin dependent kinase inhibitor 1A Homo sapiens 18-21 20459793-11 2010 The CDKN1A mRNA levels were significantly up-regulated by cisplatin/kaempferol treatment. Cisplatin 58-67 cyclin dependent kinase inhibitor 1A Homo sapiens 4-10 20811155-0 2010 Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. Cisplatin 44-53 cyclin dependent kinase inhibitor 1A Homo sapiens 12-15 20811155-4 2010 Here, we have shown that one key determinant of cisplatin-resistance in testicular embryonal carcinoma (EC) is high cytoplasmic expression of the cyclin-dependent kinase (CDK) inhibitor p21. Cisplatin 48-57 cyclin dependent kinase inhibitor 1A Homo sapiens 186-189 20811155-5 2010 The EC component of the majority of refractory testicular cancer patients exhibited high cytoplasmic p21 expression, which protected EC cell lines against cisplatin-induced apoptosis via CDK2 inhibition. Cisplatin 155-164 cyclin dependent kinase inhibitor 1A Homo sapiens 101-104 20811155-6 2010 Localization of p21 in the cytoplasm was critical for cisplatin resistance, since relocalization of p21 to the nucleus by Akt inhibition sensitized EC cell lines to cisplatin. Cisplatin 54-63 cyclin dependent kinase inhibitor 1A Homo sapiens 16-19 20811155-6 2010 Localization of p21 in the cytoplasm was critical for cisplatin resistance, since relocalization of p21 to the nucleus by Akt inhibition sensitized EC cell lines to cisplatin. Cisplatin 165-174 cyclin dependent kinase inhibitor 1A Homo sapiens 16-19 20811155-6 2010 Localization of p21 in the cytoplasm was critical for cisplatin resistance, since relocalization of p21 to the nucleus by Akt inhibition sensitized EC cell lines to cisplatin. Cisplatin 165-174 cyclin dependent kinase inhibitor 1A Homo sapiens 100-103 18499163-7 2008 RESULTS: Pre-incubation of ACHN and SN12C cells with phosphorothioate antisense p21 oligodeoxynucleotide markedly attenuated p21 and sensitized cells to the apoptosis induced by doxorubicin and cisplatin, such that an order of magnitude less of doxorubicin or cisplatin could be used in the presence of antisense to achieve equivalent or greater cell death. Cisplatin 194-203 cyclin dependent kinase inhibitor 1A Homo sapiens 80-83 19177004-9 2009 Importantly, HeLa cells with reduced level of Plk1, which induces an increase of p21, p73 and Bax, are more sensitive to some chemotherapeutic agents, such as cisplatin. Cisplatin 159-168 cyclin dependent kinase inhibitor 1A Homo sapiens 81-84 18483502-0 2008 A dual role of p21waf1/cip1 gene in apoptosis of HEp-2 treated with cisplatin or methotrexate. Cisplatin 68-77 cyclin dependent kinase inhibitor 1A Homo sapiens 23-27 18483502-4 2008 In addition, we have proved that p21(waf1/cip1) can assume a dual role in apoptosis in the same cell system depending on the chemotherapeutic agent: its overexpression enhances apoptosis in cisplatin-treated cells and attenuates apoptotic signals in methotrexate-treated cells. Cisplatin 190-199 cyclin dependent kinase inhibitor 1A Homo sapiens 33-46 18499163-7 2008 RESULTS: Pre-incubation of ACHN and SN12C cells with phosphorothioate antisense p21 oligodeoxynucleotide markedly attenuated p21 and sensitized cells to the apoptosis induced by doxorubicin and cisplatin, such that an order of magnitude less of doxorubicin or cisplatin could be used in the presence of antisense to achieve equivalent or greater cell death. Cisplatin 260-269 cyclin dependent kinase inhibitor 1A Homo sapiens 80-83 16914540-3 2006 It was shown in vivo that cisplatin administration induces upregulation of the gene for the p21 cyclin-dependent kinase (cdk) inhibitor in kidney cells. Cisplatin 26-35 cyclin dependent kinase inhibitor 1A Homo sapiens 92-95 18458079-3 2008 We have recently found that the p21-dependent checkpoint can be activated and induce a prolonged arrest if S phase cells are damaged with a base-modifying agent, such as methyl methanesulfonate (MMS) and cisplatin. Cisplatin 204-213 cyclin dependent kinase inhibitor 1A Homo sapiens 32-35 17582213-8 2007 RESULTS: The expression of CDKN1A, BAX, TNFSF8, and RRM2B was consistently upregulated by CRT (9 Gy with a single administration of cisplatin). Cisplatin 132-141 cyclin dependent kinase inhibitor 1A Homo sapiens 27-33 16914540-4 2006 This protein is a positive effector on the fate of cisplatin-exposed renal tubule cells in vivo and in vitro; adenoviral transduction of p21 completely protected proximal tubule cells from cisplatin toxicity. Cisplatin 51-60 cyclin dependent kinase inhibitor 1A Homo sapiens 137-140 16914540-4 2006 This protein is a positive effector on the fate of cisplatin-exposed renal tubule cells in vivo and in vitro; adenoviral transduction of p21 completely protected proximal tubule cells from cisplatin toxicity. Cisplatin 189-198 cyclin dependent kinase inhibitor 1A Homo sapiens 137-140 16914540-7 2006 It is concluded that cisplatin cytotoxicity depends on cdk2 activation and that the mechanism of p21 protection is by direct inhibition of cdk2. Cisplatin 21-30 cyclin dependent kinase inhibitor 1A Homo sapiens 97-100 15920103-8 2005 Transcriptional activation of p21(WAF1/CIP1) and Bax by p53 on exposure to cisplatin was completely blocked by introducing the p53 decoy oligonucleotide. Cisplatin 75-84 cyclin dependent kinase inhibitor 1A Homo sapiens 30-33 15840769-0 2005 Identification of the functional domain of p21(WAF1/CIP1) that protects cells from cisplatin cytotoxicity. Cisplatin 83-92 cyclin dependent kinase inhibitor 1A Homo sapiens 43-46 15840769-0 2005 Identification of the functional domain of p21(WAF1/CIP1) that protects cells from cisplatin cytotoxicity. Cisplatin 83-92 cyclin dependent kinase inhibitor 1A Homo sapiens 47-51 15840769-0 2005 Identification of the functional domain of p21(WAF1/CIP1) that protects cells from cisplatin cytotoxicity. Cisplatin 83-92 cyclin dependent kinase inhibitor 1A Homo sapiens 52-56 15840769-1 2005 The p21 cyclin-dependent kinase (cdk) inhibitor protects cells from cisplatin cytotoxicity in vivo and in vitro. Cisplatin 68-77 cyclin dependent kinase inhibitor 1A Homo sapiens 4-7 15840769-7 2005 The dependence of cisplatin cytotoxicity on cdk2 activity was also demonstrated because 1) cisplatin caused a marked increase in cdk2 activity, which was prevented by the p21 expression adenovirus, and 2) a cdk2 dominant-negative adenovirus also protected cells from cisplatin-induced apoptosis. Cisplatin 18-27 cyclin dependent kinase inhibitor 1A Homo sapiens 171-174 15840769-7 2005 The dependence of cisplatin cytotoxicity on cdk2 activity was also demonstrated because 1) cisplatin caused a marked increase in cdk2 activity, which was prevented by the p21 expression adenovirus, and 2) a cdk2 dominant-negative adenovirus also protected cells from cisplatin-induced apoptosis. Cisplatin 91-100 cyclin dependent kinase inhibitor 1A Homo sapiens 171-174 15840769-7 2005 The dependence of cisplatin cytotoxicity on cdk2 activity was also demonstrated because 1) cisplatin caused a marked increase in cdk2 activity, which was prevented by the p21 expression adenovirus, and 2) a cdk2 dominant-negative adenovirus also protected cells from cisplatin-induced apoptosis. Cisplatin 91-100 cyclin dependent kinase inhibitor 1A Homo sapiens 171-174 15920103-8 2005 Transcriptional activation of p21(WAF1/CIP1) and Bax by p53 on exposure to cisplatin was completely blocked by introducing the p53 decoy oligonucleotide. Cisplatin 75-84 cyclin dependent kinase inhibitor 1A Homo sapiens 34-38 15920103-8 2005 Transcriptional activation of p21(WAF1/CIP1) and Bax by p53 on exposure to cisplatin was completely blocked by introducing the p53 decoy oligonucleotide. Cisplatin 75-84 cyclin dependent kinase inhibitor 1A Homo sapiens 39-43 14576150-10 2004 Together, these data strongly suggest that endogenously produced nitric oxide is required for cisplatin-induced p53 activation and p21(Waf1/Cip1/Sdi1) expression, which can regulate melanoma sensitivity to cisplatin. Cisplatin 94-103 cyclin dependent kinase inhibitor 1A Homo sapiens 145-149 15886465-6 2005 The expression of p21(WAF1/CIP1) protein was increased only after treatment with 5-FU, not cisplatin or radiation. Cisplatin 91-100 cyclin dependent kinase inhibitor 1A Homo sapiens 18-21 15886465-6 2005 The expression of p21(WAF1/CIP1) protein was increased only after treatment with 5-FU, not cisplatin or radiation. Cisplatin 91-100 cyclin dependent kinase inhibitor 1A Homo sapiens 22-31 15886465-10 2005 Cisplatin induced p53-dependent apoptosis and p21(WAF1/CIP1)-independent S-phase cell cycle arrest and 5-FU induced p53 and p21(WAF1/CIP1)-dependent G1-phase cell cycle arrest, not apoptosis. Cisplatin 0-9 cyclin dependent kinase inhibitor 1A Homo sapiens 46-49 15886465-10 2005 Cisplatin induced p53-dependent apoptosis and p21(WAF1/CIP1)-independent S-phase cell cycle arrest and 5-FU induced p53 and p21(WAF1/CIP1)-dependent G1-phase cell cycle arrest, not apoptosis. Cisplatin 0-9 cyclin dependent kinase inhibitor 1A Homo sapiens 50-59 14576150-7 2004 Strikingly, we observed that the depletion of nitric oxide inhibits cisplatin-induced wild type p53 accumulation and p21(Waf1/Cip1/Sdi1) expression in melanoma cells. Cisplatin 68-77 cyclin dependent kinase inhibitor 1A Homo sapiens 117-120 14576150-7 2004 Strikingly, we observed that the depletion of nitric oxide inhibits cisplatin-induced wild type p53 accumulation and p21(Waf1/Cip1/Sdi1) expression in melanoma cells. Cisplatin 68-77 cyclin dependent kinase inhibitor 1A Homo sapiens 121-125 14576150-10 2004 Together, these data strongly suggest that endogenously produced nitric oxide is required for cisplatin-induced p53 activation and p21(Waf1/Cip1/Sdi1) expression, which can regulate melanoma sensitivity to cisplatin. Cisplatin 206-215 cyclin dependent kinase inhibitor 1A Homo sapiens 131-134 14576150-7 2004 Strikingly, we observed that the depletion of nitric oxide inhibits cisplatin-induced wild type p53 accumulation and p21(Waf1/Cip1/Sdi1) expression in melanoma cells. Cisplatin 68-77 cyclin dependent kinase inhibitor 1A Homo sapiens 126-130 14576150-10 2004 Together, these data strongly suggest that endogenously produced nitric oxide is required for cisplatin-induced p53 activation and p21(Waf1/Cip1/Sdi1) expression, which can regulate melanoma sensitivity to cisplatin. Cisplatin 206-215 cyclin dependent kinase inhibitor 1A Homo sapiens 135-139 14576150-7 2004 Strikingly, we observed that the depletion of nitric oxide inhibits cisplatin-induced wild type p53 accumulation and p21(Waf1/Cip1/Sdi1) expression in melanoma cells. Cisplatin 68-77 cyclin dependent kinase inhibitor 1A Homo sapiens 131-135 14576150-8 2004 When cisplatin-induced p53 binding to the p21(Waf1/Cip1/Sdi1) promoter was examined, it was found that nitric oxide depletion significantly reduced the presence of p53-DNA complexes after cisplatin treatment. Cisplatin 5-14 cyclin dependent kinase inhibitor 1A Homo sapiens 42-45 14576150-8 2004 When cisplatin-induced p53 binding to the p21(Waf1/Cip1/Sdi1) promoter was examined, it was found that nitric oxide depletion significantly reduced the presence of p53-DNA complexes after cisplatin treatment. Cisplatin 5-14 cyclin dependent kinase inhibitor 1A Homo sapiens 46-50 14576150-10 2004 Together, these data strongly suggest that endogenously produced nitric oxide is required for cisplatin-induced p53 activation and p21(Waf1/Cip1/Sdi1) expression, which can regulate melanoma sensitivity to cisplatin. Cisplatin 206-215 cyclin dependent kinase inhibitor 1A Homo sapiens 140-144 14576150-8 2004 When cisplatin-induced p53 binding to the p21(Waf1/Cip1/Sdi1) promoter was examined, it was found that nitric oxide depletion significantly reduced the presence of p53-DNA complexes after cisplatin treatment. Cisplatin 5-14 cyclin dependent kinase inhibitor 1A Homo sapiens 51-55 14576150-8 2004 When cisplatin-induced p53 binding to the p21(Waf1/Cip1/Sdi1) promoter was examined, it was found that nitric oxide depletion significantly reduced the presence of p53-DNA complexes after cisplatin treatment. Cisplatin 5-14 cyclin dependent kinase inhibitor 1A Homo sapiens 56-60 14576150-10 2004 Together, these data strongly suggest that endogenously produced nitric oxide is required for cisplatin-induced p53 activation and p21(Waf1/Cip1/Sdi1) expression, which can regulate melanoma sensitivity to cisplatin. Cisplatin 206-215 cyclin dependent kinase inhibitor 1A Homo sapiens 145-149 15314975-0 2003 Expression of p21 and bcl-2 proteins in paraffin-embedded preparations of non-small cell lung cancer in stage IIIA after Etoposide and Cisplatin induced chemotherapy. Cisplatin 135-144 cyclin dependent kinase inhibitor 1A Homo sapiens 14-17 14513366-8 2003 In marked contrast, cisplatin-mediated induction of p21(WAF1/CIP1) was minimal or absent in resistant cells, but that of Mdm2 was unaffected. Cisplatin 20-29 cyclin dependent kinase inhibitor 1A Homo sapiens 61-65 14513366-7 2003 Similarly, inductions of p21(WAF1/CIP1) and Mdm2 were observed in sensitive cells exposed to cisplatin. Cisplatin 93-102 cyclin dependent kinase inhibitor 1A Homo sapiens 25-28 14513366-7 2003 Similarly, inductions of p21(WAF1/CIP1) and Mdm2 were observed in sensitive cells exposed to cisplatin. Cisplatin 93-102 cyclin dependent kinase inhibitor 1A Homo sapiens 29-33 14513366-7 2003 Similarly, inductions of p21(WAF1/CIP1) and Mdm2 were observed in sensitive cells exposed to cisplatin. Cisplatin 93-102 cyclin dependent kinase inhibitor 1A Homo sapiens 34-38 14513366-8 2003 In marked contrast, cisplatin-mediated induction of p21(WAF1/CIP1) was minimal or absent in resistant cells, but that of Mdm2 was unaffected. Cisplatin 20-29 cyclin dependent kinase inhibitor 1A Homo sapiens 52-55 14513366-8 2003 In marked contrast, cisplatin-mediated induction of p21(WAF1/CIP1) was minimal or absent in resistant cells, but that of Mdm2 was unaffected. Cisplatin 20-29 cyclin dependent kinase inhibitor 1A Homo sapiens 56-60 12740909-8 2003 Cisplatin induced an appreciable increase of p21(WAF1) levels in both models, in contrast to BBR3464 that produced a substantial upregulation of p21(WAF1) only in parental cells. Cisplatin 0-9 cyclin dependent kinase inhibitor 1A Homo sapiens 45-48 12740909-8 2003 Cisplatin induced an appreciable increase of p21(WAF1) levels in both models, in contrast to BBR3464 that produced a substantial upregulation of p21(WAF1) only in parental cells. Cisplatin 0-9 cyclin dependent kinase inhibitor 1A Homo sapiens 49-53 12740909-9 2003 An inverse relationship with p21(WAF1) modulation was found for CHK1 in parental cells treated with both agents and in resistant cells treated with cisplatin. Cisplatin 148-157 cyclin dependent kinase inhibitor 1A Homo sapiens 29-32 12740909-9 2003 An inverse relationship with p21(WAF1) modulation was found for CHK1 in parental cells treated with both agents and in resistant cells treated with cisplatin. Cisplatin 148-157 cyclin dependent kinase inhibitor 1A Homo sapiens 33-37 12594211-4 2003 Following cisplatin treatment, induction of p73 and its downstream effector p21(Cip1) was essentially blocked in SHP-2 mutant cells. Cisplatin 10-19 cyclin dependent kinase inhibitor 1A Homo sapiens 80-84 12824923-0 2003 Enhanced sensitivity to cis-diamminedichloroplatinum(II) of a human carcinoma cell line with mutated p53 gene by cyclin-dependent kinase inhibitor p21(WAF1) expression. Cisplatin 24-52 cyclin dependent kinase inhibitor 1A Homo sapiens 147-150 12824923-0 2003 Enhanced sensitivity to cis-diamminedichloroplatinum(II) of a human carcinoma cell line with mutated p53 gene by cyclin-dependent kinase inhibitor p21(WAF1) expression. Cisplatin 24-52 cyclin dependent kinase inhibitor 1A Homo sapiens 151-155 12824923-5 2003 Dp21-1 cells with p21(WAF1) expression were more sensitive to cis-diamminedichloroplatinum(II) (CDDP) (IC(50) value, 10 microM) than those without p21(WAF1) expression (IC(50), 22 microM). Cisplatin 62-94 cyclin dependent kinase inhibitor 1A Homo sapiens 1-4 12824923-5 2003 Dp21-1 cells with p21(WAF1) expression were more sensitive to cis-diamminedichloroplatinum(II) (CDDP) (IC(50) value, 10 microM) than those without p21(WAF1) expression (IC(50), 22 microM). Cisplatin 62-94 cyclin dependent kinase inhibitor 1A Homo sapiens 22-26 12824923-5 2003 Dp21-1 cells with p21(WAF1) expression were more sensitive to cis-diamminedichloroplatinum(II) (CDDP) (IC(50) value, 10 microM) than those without p21(WAF1) expression (IC(50), 22 microM). Cisplatin 62-94 cyclin dependent kinase inhibitor 1A Homo sapiens 18-21 12824923-5 2003 Dp21-1 cells with p21(WAF1) expression were more sensitive to cis-diamminedichloroplatinum(II) (CDDP) (IC(50) value, 10 microM) than those without p21(WAF1) expression (IC(50), 22 microM). Cisplatin 96-100 cyclin dependent kinase inhibitor 1A Homo sapiens 1-4 12824923-5 2003 Dp21-1 cells with p21(WAF1) expression were more sensitive to cis-diamminedichloroplatinum(II) (CDDP) (IC(50) value, 10 microM) than those without p21(WAF1) expression (IC(50), 22 microM). Cisplatin 96-100 cyclin dependent kinase inhibitor 1A Homo sapiens 22-26 12824923-5 2003 Dp21-1 cells with p21(WAF1) expression were more sensitive to cis-diamminedichloroplatinum(II) (CDDP) (IC(50) value, 10 microM) than those without p21(WAF1) expression (IC(50), 22 microM). Cisplatin 96-100 cyclin dependent kinase inhibitor 1A Homo sapiens 18-21 12450415-10 2002 However, from a selected number of proteins involved in cell cycle regulation, DNA repair and chromatin structure, Western blot analysis showed that p21waf1/Cip1 was significantly upregulated after low dose cisplatin treatment in FA cells specifically (as well as being expressed at elevated levels in untreated FA cells). Cisplatin 207-216 cyclin dependent kinase inhibitor 1A Homo sapiens 157-161 12478472-4 2002 The cisplatin-induced protein phosphorylation, not detectable in cells treated with BBR 3464, was associated with RPA phosphorylation, a specific up-regulation of Bax and down-regulation of p21(WAF1). Cisplatin 4-13 cyclin dependent kinase inhibitor 1A Homo sapiens 190-193 12478472-4 2002 The cisplatin-induced protein phosphorylation, not detectable in cells treated with BBR 3464, was associated with RPA phosphorylation, a specific up-regulation of Bax and down-regulation of p21(WAF1). Cisplatin 4-13 cyclin dependent kinase inhibitor 1A Homo sapiens 194-198 12478472-6 2002 The regulation of p21(WAF1) after cisplatin or BBR 3464 exposure required a p53 signal, as documented using stable transfectants expressing a dominant-negative form of p53 (175(his)). Cisplatin 34-43 cyclin dependent kinase inhibitor 1A Homo sapiens 18-21 12478472-6 2002 The regulation of p21(WAF1) after cisplatin or BBR 3464 exposure required a p53 signal, as documented using stable transfectants expressing a dominant-negative form of p53 (175(his)). Cisplatin 34-43 cyclin dependent kinase inhibitor 1A Homo sapiens 22-26 11595124-0 2001 Exogenous expression of p21(WAF1/CIP1) exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cisplatin 97-106 cyclin dependent kinase inhibitor 1A Homo sapiens 24-27 12007018-10 2002 Cisplatin-induced p21 transactivation assays and G(1) cell cycle arrest analyses showed that p21 transactivation and G(1) arrest occurred in both CCSK and CMN cultures, demonstrating integrity of the p53 signal transduction pathway. Cisplatin 0-9 cyclin dependent kinase inhibitor 1A Homo sapiens 18-21 12007018-10 2002 Cisplatin-induced p21 transactivation assays and G(1) cell cycle arrest analyses showed that p21 transactivation and G(1) arrest occurred in both CCSK and CMN cultures, demonstrating integrity of the p53 signal transduction pathway. Cisplatin 0-9 cyclin dependent kinase inhibitor 1A Homo sapiens 93-96 11734333-5 2002 Low-dose cisplatin induced a transient G(1) arrest, S phase block and upregulation of p53 and p21(WAF1/CIP1) expression in HepG2, but not in Hep3B cells. Cisplatin 9-18 cyclin dependent kinase inhibitor 1A Homo sapiens 94-97 11734333-5 2002 Low-dose cisplatin induced a transient G(1) arrest, S phase block and upregulation of p53 and p21(WAF1/CIP1) expression in HepG2, but not in Hep3B cells. Cisplatin 9-18 cyclin dependent kinase inhibitor 1A Homo sapiens 98-107 11734333-7 2002 In HepG2, upregulation of p53 and p21(WAF1/CIP1) was observed before apoptosis occurred, suggesting that cisplatin-induced apoptosis in HepG2 might be p53-dependent. Cisplatin 105-114 cyclin dependent kinase inhibitor 1A Homo sapiens 34-37 11734333-7 2002 In HepG2, upregulation of p53 and p21(WAF1/CIP1) was observed before apoptosis occurred, suggesting that cisplatin-induced apoptosis in HepG2 might be p53-dependent. Cisplatin 105-114 cyclin dependent kinase inhibitor 1A Homo sapiens 38-42 11734333-7 2002 In HepG2, upregulation of p53 and p21(WAF1/CIP1) was observed before apoptosis occurred, suggesting that cisplatin-induced apoptosis in HepG2 might be p53-dependent. Cisplatin 105-114 cyclin dependent kinase inhibitor 1A Homo sapiens 43-47 11559705-3 2001 We found that expression of wild-type p21 (p21(WT)), not mutant p21 (p21(PCNA-)) lacking the interaction with proliferating cell nuclear antigen (PCNA), caused G(2) cell cycle arrest in p53-deficient DLD1 colon cancer cell line after the DNA damage by treatment with cis-diamminedichloroplatinum (II). Cisplatin 267-295 cyclin dependent kinase inhibitor 1A Homo sapiens 38-41 11595124-6 2001 These findings raise the potential that forced upregulation of p21(WAF1/CIP1) in hepatocellular carcinoma (HCC) may reduce the doses of cisplatin to achieve similar responses and suggest the possible use of p21(WAF1/CIP1) in HCC treatment. Cisplatin 136-145 cyclin dependent kinase inhibitor 1A Homo sapiens 63-66 11595124-6 2001 These findings raise the potential that forced upregulation of p21(WAF1/CIP1) in hepatocellular carcinoma (HCC) may reduce the doses of cisplatin to achieve similar responses and suggest the possible use of p21(WAF1/CIP1) in HCC treatment. Cisplatin 136-145 cyclin dependent kinase inhibitor 1A Homo sapiens 67-76 11595124-6 2001 These findings raise the potential that forced upregulation of p21(WAF1/CIP1) in hepatocellular carcinoma (HCC) may reduce the doses of cisplatin to achieve similar responses and suggest the possible use of p21(WAF1/CIP1) in HCC treatment. Cisplatin 136-145 cyclin dependent kinase inhibitor 1A Homo sapiens 67-71 11595124-6 2001 These findings raise the potential that forced upregulation of p21(WAF1/CIP1) in hepatocellular carcinoma (HCC) may reduce the doses of cisplatin to achieve similar responses and suggest the possible use of p21(WAF1/CIP1) in HCC treatment. Cisplatin 136-145 cyclin dependent kinase inhibitor 1A Homo sapiens 72-76 11595124-0 2001 Exogenous expression of p21(WAF1/CIP1) exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cisplatin 97-106 cyclin dependent kinase inhibitor 1A Homo sapiens 28-32 11595124-0 2001 Exogenous expression of p21(WAF1/CIP1) exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cisplatin 97-106 cyclin dependent kinase inhibitor 1A Homo sapiens 33-37 11595124-4 2001 Exogenous p21(WAF1/CIP1) expression also significantly enhanced chemosensitivity to cisplatin. Cisplatin 84-93 cyclin dependent kinase inhibitor 1A Homo sapiens 10-13 11595124-4 2001 Exogenous p21(WAF1/CIP1) expression also significantly enhanced chemosensitivity to cisplatin. Cisplatin 84-93 cyclin dependent kinase inhibitor 1A Homo sapiens 14-18 11595124-4 2001 Exogenous p21(WAF1/CIP1) expression also significantly enhanced chemosensitivity to cisplatin. Cisplatin 84-93 cyclin dependent kinase inhibitor 1A Homo sapiens 19-23 11595124-5 2001 In addition, apoptosis occurred earlier in cells transfected with p21(WAF1/CIP1) after cisplatin treatment. Cisplatin 87-96 cyclin dependent kinase inhibitor 1A Homo sapiens 66-69 11595124-5 2001 In addition, apoptosis occurred earlier in cells transfected with p21(WAF1/CIP1) after cisplatin treatment. Cisplatin 87-96 cyclin dependent kinase inhibitor 1A Homo sapiens 70-74 11595124-5 2001 In addition, apoptosis occurred earlier in cells transfected with p21(WAF1/CIP1) after cisplatin treatment. Cisplatin 87-96 cyclin dependent kinase inhibitor 1A Homo sapiens 75-79 11099651-10 2000 Many of the "fingerprint genes" identified in these studies were consistent with previous observations reported in the literature (e. g., the well-characterized induction by cisplatin of p53-regulated transcripts such as p21(waf1/cip1) and PCNA [proliferating cell nuclear antigen]). Cisplatin 174-183 cyclin dependent kinase inhibitor 1A Homo sapiens 221-234 11593424-7 2001 Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells. Cisplatin 95-104 cyclin dependent kinase inhibitor 1A Homo sapiens 25-28 11593424-7 2001 Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells. Cisplatin 95-104 cyclin dependent kinase inhibitor 1A Homo sapiens 29-33 11078909-0 2000 The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cisplatin 86-95 cyclin dependent kinase inhibitor 1A Homo sapiens 4-7 11078909-0 2000 The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cisplatin 86-95 cyclin dependent kinase inhibitor 1A Homo sapiens 8-12 11078909-0 2000 The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cisplatin 86-95 cyclin dependent kinase inhibitor 1A Homo sapiens 13-17 11078909-2 2000 The transfection of p21(cip1/waf1) cDNA into SKOV3 and OVCAR3 cells led to reduction of tumor cell growth, enhanced susceptibility to cisplatin-induced apoptosis, and abolition of recurrency after cisplatin exposure. Cisplatin 134-143 cyclin dependent kinase inhibitor 1A Homo sapiens 20-23 11078909-2 2000 The transfection of p21(cip1/waf1) cDNA into SKOV3 and OVCAR3 cells led to reduction of tumor cell growth, enhanced susceptibility to cisplatin-induced apoptosis, and abolition of recurrency after cisplatin exposure. Cisplatin 134-143 cyclin dependent kinase inhibitor 1A Homo sapiens 24-28 11078909-2 2000 The transfection of p21(cip1/waf1) cDNA into SKOV3 and OVCAR3 cells led to reduction of tumor cell growth, enhanced susceptibility to cisplatin-induced apoptosis, and abolition of recurrency after cisplatin exposure. Cisplatin 134-143 cyclin dependent kinase inhibitor 1A Homo sapiens 29-33 11078909-2 2000 The transfection of p21(cip1/waf1) cDNA into SKOV3 and OVCAR3 cells led to reduction of tumor cell growth, enhanced susceptibility to cisplatin-induced apoptosis, and abolition of recurrency after cisplatin exposure. Cisplatin 197-206 cyclin dependent kinase inhibitor 1A Homo sapiens 20-23 11078909-2 2000 The transfection of p21(cip1/waf1) cDNA into SKOV3 and OVCAR3 cells led to reduction of tumor cell growth, enhanced susceptibility to cisplatin-induced apoptosis, and abolition of recurrency after cisplatin exposure. Cisplatin 197-206 cyclin dependent kinase inhibitor 1A Homo sapiens 24-28 11078909-2 2000 The transfection of p21(cip1/waf1) cDNA into SKOV3 and OVCAR3 cells led to reduction of tumor cell growth, enhanced susceptibility to cisplatin-induced apoptosis, and abolition of recurrency after cisplatin exposure. Cisplatin 197-206 cyclin dependent kinase inhibitor 1A Homo sapiens 29-33 11078909-3 2000 p21(cip1/waf1) gene transfer allowed a marked reduction of the cisplatin concentration needed to erradicate the tumor cell population. Cisplatin 63-72 cyclin dependent kinase inhibitor 1A Homo sapiens 0-3 11078909-3 2000 p21(cip1/waf1) gene transfer allowed a marked reduction of the cisplatin concentration needed to erradicate the tumor cell population. Cisplatin 63-72 cyclin dependent kinase inhibitor 1A Homo sapiens 4-8 11078909-3 2000 p21(cip1/waf1) gene transfer allowed a marked reduction of the cisplatin concentration needed to erradicate the tumor cell population. Cisplatin 63-72 cyclin dependent kinase inhibitor 1A Homo sapiens 9-13 9537261-3 1998 Our results showed that the induction of WAF1/Cip1 expression rendered glioma cells resistant to cell death induced by BCNU and cisplatin. Cisplatin 128-137 cyclin dependent kinase inhibitor 1A Homo sapiens 41-45 11034077-0 2000 The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cisplatin 138-147 cyclin dependent kinase inhibitor 1A Homo sapiens 117-121 11034077-0 2000 The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cisplatin 138-147 cyclin dependent kinase inhibitor 1A Homo sapiens 122-126 11034077-3 2000 Here, we demonstrate that phosphatidylinositol 3-kinase (PI3K) and its downstream targets serine/threonine kinases AKT1 and AKT2 (AKT), are required for the full induction of p21 in A2780 cells treated with cisplatin or paclitaxel. Cisplatin 207-216 cyclin dependent kinase inhibitor 1A Homo sapiens 175-178 11034077-6 2000 Experiments with additional ovarian carcinoma cell lines revealed that PI3K is involved in the expression of p21 induced by cisplatin or paclitaxel in OVCAR-10 cells, which have wild-type p53, but not in OVCAR-5 cells, which lack functional p53. Cisplatin 124-133 cyclin dependent kinase inhibitor 1A Homo sapiens 109-112 10810363-5 2000 Exposure of U2-OS osteosarcoma cells to DNA damaging agents, cisplatin or mitomycin C, caused upregulated expression of Mdm2 and p21WAF1/CIP1. Cisplatin 61-70 cyclin dependent kinase inhibitor 1A Homo sapiens 137-141 9918219-0 1999 Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cisplatin 200-209 cyclin dependent kinase inhibitor 1A Homo sapiens 15-19 9918219-0 1999 Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cisplatin 200-209 cyclin dependent kinase inhibitor 1A Homo sapiens 20-24 9811465-6 1998 A lower basal level and reduced magnitude of protein induction of the cell cycle inhibitor p21/Waf1 was seen both after cisplatin and gamma-radiation treatment in the mutant p53 expressing lymphoblastoid variant when compared to the wild type p53 parental cell line but induction of the p53 regulator MDM2 was comparable in both. Cisplatin 120-129 cyclin dependent kinase inhibitor 1A Homo sapiens 91-94 9811465-6 1998 A lower basal level and reduced magnitude of protein induction of the cell cycle inhibitor p21/Waf1 was seen both after cisplatin and gamma-radiation treatment in the mutant p53 expressing lymphoblastoid variant when compared to the wild type p53 parental cell line but induction of the p53 regulator MDM2 was comparable in both. Cisplatin 120-129 cyclin dependent kinase inhibitor 1A Homo sapiens 95-99 9537261-0 1998 Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cisplatin 125-134 cyclin dependent kinase inhibitor 1A Homo sapiens 14-18 9537261-0 1998 Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cisplatin 125-134 cyclin dependent kinase inhibitor 1A Homo sapiens 19-23 9918219-11 1999 Our results show that the attenuation of WAF1/Cip1 expression initiated glioma cell death and sensitized glioma cells to apoptosis induced by 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cisplatin 183-192 cyclin dependent kinase inhibitor 1A Homo sapiens 41-45 9918219-11 1999 Our results show that the attenuation of WAF1/Cip1 expression initiated glioma cell death and sensitized glioma cells to apoptosis induced by 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cisplatin 183-192 cyclin dependent kinase inhibitor 1A Homo sapiens 46-50 9537261-3 1998 Our results showed that the induction of WAF1/Cip1 expression rendered glioma cells resistant to cell death induced by BCNU and cisplatin. Cisplatin 128-137 cyclin dependent kinase inhibitor 1A Homo sapiens 46-50 9537261-5 1998 We conclude that WAF1/Cip1 allows repair of BCNU- and cisplatin-damaged DNA and protects glioma cells from chemotherapy agent-induced apoptosis. Cisplatin 54-63 cyclin dependent kinase inhibitor 1A Homo sapiens 17-21 9537261-5 1998 We conclude that WAF1/Cip1 allows repair of BCNU- and cisplatin-damaged DNA and protects glioma cells from chemotherapy agent-induced apoptosis. Cisplatin 54-63 cyclin dependent kinase inhibitor 1A Homo sapiens 22-26 9223430-4 1997 Northern blot analysis revealed that p21(Waf1/Cip1) and E1AF were correlatively upregulated in response to cisplatin treatment in SiHa cells. Cisplatin 107-116 cyclin dependent kinase inhibitor 1A Homo sapiens 37-40 9212237-7 1997 At the same time, we found strong induction of p53, waf-1 and bax protein levels after CDDP treatment in the A2780, but not in the A2780-DX3, cell line. Cisplatin 87-91 cyclin dependent kinase inhibitor 1A Homo sapiens 52-57 9223430-4 1997 Northern blot analysis revealed that p21(Waf1/Cip1) and E1AF were correlatively upregulated in response to cisplatin treatment in SiHa cells. Cisplatin 107-116 cyclin dependent kinase inhibitor 1A Homo sapiens 46-50 9223430-4 1997 Northern blot analysis revealed that p21(Waf1/Cip1) and E1AF were correlatively upregulated in response to cisplatin treatment in SiHa cells. Cisplatin 107-116 cyclin dependent kinase inhibitor 1A Homo sapiens 41-45 9186003-3 1997 Cisplatin-treated cells arrest in the G1 phase of the cell cycle, most likely due to a signal generated by the stabilization of p53 and the subsequent induction of p21WAF-1/Cip1. Cisplatin 0-9 cyclin dependent kinase inhibitor 1A Homo sapiens 164-177 9252645-6 1997 Further experiments showed that cisplatin induction of the immediate early genes c-jun and p21cip1 was not affected by BZA-5B. Cisplatin 32-41 cyclin dependent kinase inhibitor 1A Homo sapiens 91-98 8808702-6 1996 In this study, we show that WAF1/CIP1 was induced in p53-dependent apoptosis of U87-MG glioma cells by cis-diamminedichloroplatinum (cisplatin), and overexpression of WAF1/CIP1 induced apoptosis in U87-MG cells without cisplatin treatment. Cisplatin 133-142 cyclin dependent kinase inhibitor 1A Homo sapiens 28-32 9174048-6 1997 HCT-116 cells with disrupted p21 genes also exhibited greater CDDP and HN2-sensitivity than parental HCT-116 cells. Cisplatin 62-66 cyclin dependent kinase inhibitor 1A Homo sapiens 29-32 9174048-8 1997 Sensitization of HCT-116/p21-/- cells to CDDP and HN2 was not limited to the HCT-116 cell background since MEF from p21 knockout mice were also more sensitive to these DNA crosslinking agents. Cisplatin 41-45 cyclin dependent kinase inhibitor 1A Homo sapiens 25-28 9174048-9 1997 Investigations into a possible cause of this enhanced sensitivity revealed that HCT-116 cells lacking p53 or p21 function exhibited a reduced ability to repair cisplatin-damaged CAT-reporter plasmids transfected into the cells. Cisplatin 160-169 cyclin dependent kinase inhibitor 1A Homo sapiens 109-112 8950204-0 1996 High-risk HPV-positive human cancer cell lines show different sensitivity to cisplatin-induced apoptosis correlated with the p21Waf1/Cip1 level. Cisplatin 77-86 cyclin dependent kinase inhibitor 1A Homo sapiens 133-137 8950204-4 1996 Northern blot analyses showed that p53 and p21Waf1/Cip1 mRNA were detectable in all untreated cells, and increasing amounts of these transcripts were identified in all cell lines treated with cisplatin. Cisplatin 192-201 cyclin dependent kinase inhibitor 1A Homo sapiens 51-55 8950204-7 1996 Our results show that there were differences in sensitivity to cisplatin among four types of high risk HPV-positive cells, possibly due to different levels of p21Waf1/Cip1 up-regulation by functional p53. Cisplatin 63-72 cyclin dependent kinase inhibitor 1A Homo sapiens 167-171 9174048-0 1997 Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Cisplatin 66-75 cyclin dependent kinase inhibitor 1A Homo sapiens 14-18 9174048-0 1997 Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Cisplatin 66-75 cyclin dependent kinase inhibitor 1A Homo sapiens 19-23 8945622-4 1996 When exposed to DNA-damaging agents, cisplatin or mitomycin C, apoptosis was induced in RT4 with the wild-type (wt) p53/wt p21, whereas T24 with the p53 non-sense mutation/wt p21 was resistant. Cisplatin 37-46 cyclin dependent kinase inhibitor 1A Homo sapiens 123-126 8945622-4 1996 When exposed to DNA-damaging agents, cisplatin or mitomycin C, apoptosis was induced in RT4 with the wild-type (wt) p53/wt p21, whereas T24 with the p53 non-sense mutation/wt p21 was resistant. Cisplatin 37-46 cyclin dependent kinase inhibitor 1A Homo sapiens 175-178 8808702-0 1996 WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Cisplatin 87-96 cyclin dependent kinase inhibitor 1A Homo sapiens 0-4 8808702-0 1996 WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Cisplatin 87-96 cyclin dependent kinase inhibitor 1A Homo sapiens 5-9 8808702-6 1996 In this study, we show that WAF1/CIP1 was induced in p53-dependent apoptosis of U87-MG glioma cells by cis-diamminedichloroplatinum (cisplatin), and overexpression of WAF1/CIP1 induced apoptosis in U87-MG cells without cisplatin treatment. Cisplatin 103-131 cyclin dependent kinase inhibitor 1A Homo sapiens 28-32 8808702-6 1996 In this study, we show that WAF1/CIP1 was induced in p53-dependent apoptosis of U87-MG glioma cells by cis-diamminedichloroplatinum (cisplatin), and overexpression of WAF1/CIP1 induced apoptosis in U87-MG cells without cisplatin treatment. Cisplatin 103-131 cyclin dependent kinase inhibitor 1A Homo sapiens 33-37 8808702-6 1996 In this study, we show that WAF1/CIP1 was induced in p53-dependent apoptosis of U87-MG glioma cells by cis-diamminedichloroplatinum (cisplatin), and overexpression of WAF1/CIP1 induced apoptosis in U87-MG cells without cisplatin treatment. Cisplatin 133-142 cyclin dependent kinase inhibitor 1A Homo sapiens 33-37 8808702-6 1996 In this study, we show that WAF1/CIP1 was induced in p53-dependent apoptosis of U87-MG glioma cells by cis-diamminedichloroplatinum (cisplatin), and overexpression of WAF1/CIP1 induced apoptosis in U87-MG cells without cisplatin treatment. Cisplatin 219-228 cyclin dependent kinase inhibitor 1A Homo sapiens 28-32 8808702-6 1996 In this study, we show that WAF1/CIP1 was induced in p53-dependent apoptosis of U87-MG glioma cells by cis-diamminedichloroplatinum (cisplatin), and overexpression of WAF1/CIP1 induced apoptosis in U87-MG cells without cisplatin treatment. Cisplatin 219-228 cyclin dependent kinase inhibitor 1A Homo sapiens 33-37 8808702-9 1996 Interestingly, WAF1/CIP1 increased the susceptibility of GB-1 cells to cisplatin-induced apoptosis. Cisplatin 71-80 cyclin dependent kinase inhibitor 1A Homo sapiens 15-19 8808702-9 1996 Interestingly, WAF1/CIP1 increased the susceptibility of GB-1 cells to cisplatin-induced apoptosis. Cisplatin 71-80 cyclin dependent kinase inhibitor 1A Homo sapiens 20-24 34789301-9 2021 However, under the treatment of ghrelin, cisplatin treatment exhibited a stronger effect on inhibiting P21 expression, upregulating p-CDK1 and cyclin B1 expression, and blocking cell cycle progression. Cisplatin 41-50 cyclin dependent kinase inhibitor 1A Homo sapiens 103-106 8625293-4 1996 Introduction of UV-damaged or cisplatinum-damaged cytomegalovirus-driven beta-galactosidase reporter DNA into tumor cells revealed a significant decrease (2-5-fold) in reporter expression in p21 -/- versus +/+ cells. Cisplatin 30-41 cyclin dependent kinase inhibitor 1A Homo sapiens 191-194 34798882-0 2021 MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A. Cisplatin 24-33 cyclin dependent kinase inhibitor 1A Homo sapiens 104-110 34798882-12 2021 CONCLUSION: In brief, miR-149-3p promoted cisplatin resistance and EMT in OC by downregulating CDKN1A and TIMP2, which might provide a potential therapeutic target for OC treatment. Cisplatin 42-51 cyclin dependent kinase inhibitor 1A Homo sapiens 95-101 34873472-11 2021 We propose that patients with co-occurrence of CDKN1A and RB1 truncations may display enhanced responsiveness to targeted therapies combining cisplatin with ATR, ATM, CHK1, and CHK2 inhibitors, expanding therapeutic options for patients in need of improved precision treatments. Cisplatin 142-151 cyclin dependent kinase inhibitor 1A Homo sapiens 47-53 34261004-0 2021 Cisplatin"s potential for type 2 diabetes repositioning by inhibiting CDKN1A, FAS, and SESN1. Cisplatin 0-9 cyclin dependent kinase inhibitor 1A Homo sapiens 70-76 34445588-5 2021 It describes a protein-protein interaction network that indicates highly dysregulated TP53, MDM2, and CDKN1A genes as they encode the top networking proteins that may be involved in cisplatin tolerance, these all being upregulated in cisplatin-resistant cells. Cisplatin 182-191 cyclin dependent kinase inhibitor 1A Homo sapiens 102-108 34445588-5 2021 It describes a protein-protein interaction network that indicates highly dysregulated TP53, MDM2, and CDKN1A genes as they encode the top networking proteins that may be involved in cisplatin tolerance, these all being upregulated in cisplatin-resistant cells. Cisplatin 234-243 cyclin dependent kinase inhibitor 1A Homo sapiens 102-108 34261004-5 2021 From a list of differential expressed genes, cisplatin downregulated the cyclin-dependent kinase inhibitor 1 (CDKN1A), tumor necrosis factor (FAS), and sestrin-1 (SESN1) genes responsible for modifying signaling pathways, including the p53, JAK-STAT, FOXO, MAPK, mTOR, P13-AKT, Toll-like receptor (TLR), adipocytokine, and insulin signaling pathways. Cisplatin 45-54 cyclin dependent kinase inhibitor 1A Homo sapiens 110-116 34261004-10 2021 Cisplatin, by inhibiting CDKN1A, FAS, and SESN1, promotes IRS and PRK activity in a similar way to rosiglitazone (a popular drug used for T2DM treatment). Cisplatin 0-9 cyclin dependent kinase inhibitor 1A Homo sapiens 25-31 34261004-5 2021 From a list of differential expressed genes, cisplatin downregulated the cyclin-dependent kinase inhibitor 1 (CDKN1A), tumor necrosis factor (FAS), and sestrin-1 (SESN1) genes responsible for modifying signaling pathways, including the p53, JAK-STAT, FOXO, MAPK, mTOR, P13-AKT, Toll-like receptor (TLR), adipocytokine, and insulin signaling pathways. Cisplatin 45-54 cyclin dependent kinase inhibitor 1A Homo sapiens 73-108 35505963-5 2022 Through RNA sequencing in cells and single-cell sequencing of samples from patients with CDDP/PEM treatments, we observed CDDP/PEM-induced upregulation of CDKN1A and KEAP1, which in turn activated cell-cycle arrest and ferroptosis, respectively, thus leading to cell death. Cisplatin 89-93 cyclin dependent kinase inhibitor 1A Homo sapiens 155-161 35505963-5 2022 Through RNA sequencing in cells and single-cell sequencing of samples from patients with CDDP/PEM treatments, we observed CDDP/PEM-induced upregulation of CDKN1A and KEAP1, which in turn activated cell-cycle arrest and ferroptosis, respectively, thus leading to cell death. Cisplatin 122-126 cyclin dependent kinase inhibitor 1A Homo sapiens 155-161 35505963-7 2022 Furthermore, we demonstrated that miR-6077 protects LUAD cells from cell death induced by CDDP/PEM via CDKN1A-CDK1-mediated cell-cycle arrest and KEAP1-NRF2-SLC7A11/NQO1-mediated ferroptosis, thus resulting in chemoresistance in multiple LUAD cells both in vitro and in vivo. Cisplatin 90-94 cyclin dependent kinase inhibitor 1A Homo sapiens 103-109 33994369-7 2021 Cell cycle arrest was related to the restriction of E2F-1 action by the cyclin-dependent protein kinase inhibitor p21WAF1/CIP1 Cisplatin induced apoptosis of PC9 cells by upregulating Fas, FasL, Bak, and tBID expression and PARP proteolytic cleavage. Cisplatin 127-136 cyclin dependent kinase inhibitor 1A Homo sapiens 114-126 33272936-0 2021 Differential effects of clinically-relevant N- vs C-terminal truncating CDKN1A mutations on cisplatin sensitivity in bladder cancer. Cisplatin 92-101 cyclin dependent kinase inhibitor 1A Homo sapiens 72-78 33906321-10 2021 EGCG combined with DDP treatment caused cell cycle arrest in G1 phase in BGC-823 cells, increase of apoptosis (21.3%) vs EGCG (7.25%) and DDP (3.86%) single-use group (p <0.01), up-regulated gene and protein expressions of p19Arf, p53, p21Cip1 (p <0.01). Cisplatin 19-22 cyclin dependent kinase inhibitor 1A Homo sapiens 236-243 33272936-6 2021 We found that p21-deficient cells (sg12) were sensitized to cisplatin, while cells harboring distally truncated p21 (sg109 clones) demonstrated enhanced cisplatin resistance. Cisplatin 60-69 cyclin dependent kinase inhibitor 1A Homo sapiens 14-17 33272936-6 2021 We found that p21-deficient cells (sg12) were sensitized to cisplatin, while cells harboring distally truncated p21 (sg109 clones) demonstrated enhanced cisplatin resistance. Cisplatin 153-162 cyclin dependent kinase inhibitor 1A Homo sapiens 112-115 33272936-7 2021 p21-deficient sg12 clones demonstrated less repair of DNA-platinum adducts and increased -H2AX foci after cisplatin exposure, suggesting there was persistent DNA damage after p21 loss. Cisplatin 106-115 cyclin dependent kinase inhibitor 1A Homo sapiens 0-3 33272936-8 2021 p21-deficient sg12 clones were also unable to prevent the activation of CDK1 after DNA damage, and therefore, continued through the cell cycle, resulting in replication fork collapse, potentially explaining the observed cisplatin sensitization. Cisplatin 220-229 cyclin dependent kinase inhibitor 1A Homo sapiens 0-3 33272936-10 2021 Our findings suggest that different CDKN1A truncations have different and perhaps disparate biology, and that there may be a duality of effect on cisplatin sensitivity depending on mutation context. Cisplatin 146-155 cyclin dependent kinase inhibitor 1A Homo sapiens 36-42 33272936-11 2021 Implications: Truncating CDKN1A mutations generate a retained peptide that may have neomorphic functions and impact cisplatin sensitivity in patients with bladder cancer. Cisplatin 116-125 cyclin dependent kinase inhibitor 1A Homo sapiens 25-31 33277461-9 2020 Ectopic expression of p21WAF1/CIP1 in CDDP-treated ATG5-shRNA/A2780-CP20 cells increased expression of gammaH2AX and caspase-3 activity, demonstrating increased DNA damage and cell death. Cisplatin 38-42 cyclin dependent kinase inhibitor 1A Homo sapiens 22-34 31380278-8 2019 The cisplatin-treated-H cybrids had elevated expression of CDKN1A/P21, which has a role in cisplatin toxicity, compared to untreated-H cybrids. Cisplatin 4-13 cyclin dependent kinase inhibitor 1A Homo sapiens 59-65 33174043-9 2020 Cisplatin increased the expression of genes related to the p53 and FoxO pathways, such as Fas, p21/CDKN1A, and Bcl-2 binding component 3, but decreased the expression of insulin-like growth factor 1 (IGF1), as well as genes in the histone (Hist)1 and Hist2 clusters. Cisplatin 0-9 cyclin dependent kinase inhibitor 1A Homo sapiens 95-98 33174043-9 2020 Cisplatin increased the expression of genes related to the p53 and FoxO pathways, such as Fas, p21/CDKN1A, and Bcl-2 binding component 3, but decreased the expression of insulin-like growth factor 1 (IGF1), as well as genes in the histone (Hist)1 and Hist2 clusters. Cisplatin 0-9 cyclin dependent kinase inhibitor 1A Homo sapiens 99-105 32236605-8 2020 On the whole, these data suggest that CDKN1A plays a role in the response to the cisplatin-pemetrexed combination in advanced KRAS-mutated NSCLC, thus suggesting that it may be used as a promising predictive marker. Cisplatin 81-90 cyclin dependent kinase inhibitor 1A Homo sapiens 38-44 31127646-8 2019 H-1E8 and L-2B4 cells treated by cisplatin showed the greatly decreased levels of hsa-miR-92b-3p and hsa-let-7a-5p; however, in contrast to 2B4 cells, 1E8 cells did not negatively regulate the increase in the expression levels of the targets GSTM3 and CDKN1A. Cisplatin 33-42 cyclin dependent kinase inhibitor 1A Homo sapiens 252-258 31380278-8 2019 The cisplatin-treated-H cybrids had elevated expression of CDKN1A/P21, which has a role in cisplatin toxicity, compared to untreated-H cybrids. Cisplatin 91-100 cyclin dependent kinase inhibitor 1A Homo sapiens 59-65 31285951-9 2019 Interestingly, ESCC cells overexpressed CDKN1A, ELAVL2 or TSPAN4 also acquired resistance to cisplatin (DDP). Cisplatin 93-102 cyclin dependent kinase inhibitor 1A Homo sapiens 40-46